Amicus Therapeutics Inc (FOLD)
10.35
-0.05
(-0.48%)
USD |
NASDAQ |
May 06, 15:40
Amicus Therapeutics Research and Development Expense (Quarterly): 35.03M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 35.03M |
| September 30, 2023 | 40.70M |
| June 30, 2023 | 35.15M |
| March 31, 2023 | 41.50M |
| December 31, 2022 | 63.87M |
| September 30, 2022 | 52.97M |
| June 30, 2022 | 78.32M |
| March 31, 2022 | 81.52M |
| December 31, 2021 | 85.60M |
| September 30, 2021 | 59.33M |
| June 30, 2021 | 63.00M |
| March 31, 2021 | 64.12M |
| December 31, 2020 | 79.29M |
| September 30, 2020 | 70.42M |
| June 30, 2020 | 69.61M |
| March 31, 2020 | 89.12M |
| December 31, 2019 | 91.91M |
| September 30, 2019 | 58.89M |
| June 30, 2019 | 70.98M |
| March 31, 2019 | 64.59M |
| December 31, 2018 | 57.22M |
| September 30, 2018 | 138.23M |
| June 30, 2018 | 34.66M |
| March 31, 2018 | 40.80M |
| December 31, 2017 | 45.81M |
| Date | Value |
|---|---|
| September 30, 2017 | 40.64M |
| June 30, 2017 | 31.98M |
| March 31, 2017 | 30.88M |
| December 31, 2016 | 30.63M |
| September 30, 2016 | 32.46M |
| June 30, 2016 | 18.28M |
| March 31, 2016 | 23.42M |
| December 31, 2015 | 22.62M |
| September 30, 2015 | 20.97M |
| June 30, 2015 | 17.23M |
| March 31, 2015 | 16.11M |
| December 31, 2014 | 15.60M |
| September 30, 2014 | 12.05M |
| June 30, 2014 | 9.978M |
| March 31, 2014 | 9.992M |
| December 31, 2013 | 9.12M |
| September 30, 2013 | 10.11M |
| June 30, 2013 | 10.72M |
| March 31, 2013 | 11.99M |
| December 31, 2012 | 11.05M |
| September 30, 2012 | 11.50M |
| June 30, 2012 | 13.72M |
| March 31, 2012 | 14.00M |
| December 31, 2011 | 14.40M |
| September 30, 2011 | 13.71M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
35.03M
Minimum
Dec 2023
91.91M
Maximum
Dec 2019
64.81M
Average
64.12M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| TG Therapeutics Inc | 32.72M |
| Geron Corp | 29.37M |
| Vanda Pharmaceuticals Inc | 24.34M |
| Fate Therapeutics Inc | 31.82M |
| Editas Medicine Inc | 69.56M |